Göran is currently Chief Executive Officer at Cantargia AB, Lund, Sweden. Cantargia is a listed biotech company developing monoclonal antibodies for the treatment of cancer and autoimmune diseases. Göran holds a Ph.D. in Biochemistry from the Royal Institute of Technology, Stockholm, Sweden, is associated professor in Biotechnology at Lund University, faculty of engineering and has authored approximately 40 scientific articles primarily within biochemistry, molecular biology, immunology and cancer research. He has worked in the pharmaceutical industry for almost 30 years in several different roles e.g. scientist, project leader, department head within KabiGen, Pharmacia, University of Adelaide and Active Biotech. Between 2008 and 2014, he was part of Active Biotech's management team and responsible for business development.